332013-37-3

Basic information

• Product Name: 1-Isoquinolinamine, 4-bromo-N-(4-chlorophenyl)-
• CAS NO: 332013-37-3
• Molecular Formula: C15H10BrClN2
• Molecular Weight: 333.615
• Mol File: 332013-37-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Isoquinolinamine, 4-bromo-N-(4-chlorophenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Isoquinolinamine, 4-bromo-N-(4-chlorophenyl)-(332013-37-3)
• EPA Substance Registry System: 1-Isoquinolinamine, 4-bromo-N-(4-chlorophenyl)-(332013-37-3)

Safety Data

• Hazardous Substances Data: 332013-37-3(Hazardous Substances Data)

Upstream product

• 491-30-5 1-isoquinolone 
• 51206-40-7 1,4-dibromoisoquinoline 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 332012-28-9 1-(4-chlorophenylamino)-4-(pyridin-4-ylthio)isoquinoline 

Relevant articles and documents

SUBSTITUTED PYRIDINES AND PYRIDAZINES WITH ANGIOGENESIS INHIBITING ACTIVITY

Substituted pyridines and pyridazines having angiogenesis inhibiting activity and generalized structural formula (I) wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R and R may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermeability processes using these materials are also disclosed.

Substituted pyridines and pyridazines with angiogenesis inhibiting activity

Substituted pyridazines having angiogenesis inhibiting activity and the generalized structural formula wherein the ring containing A, B, D, E, and L is phenyl or a nitrogen-containing heterocycle; groups X and Y may be any of a variety of defined linking units; R1and R2may be defined independent substituents or together may be a ring-defining bridge; ring J may be an aryl, pyridyl, or cycloalkyl group; and G groups may be any of a variety of defined substituents. Pharmaceutical compositions containing these materials, and methods of treating a mammal having a condition characterized by abnormal angiogenesis or hyperpermiability processes using these materials are also disclosed.